mild Alzheimers disease Hachimijiogan, mild Alzheimers disease
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1) 60 to under 85 years old 2) Patients with Alzheimers dementia (those who meet the diagnostic criteria for Alzheimers dementia according to DSM-5) 3) Those with a baseline MMSE score of 15 to 26 4) Those with a baseline ABC dementia scale score of 86 to 100 or CDR 1.0 5) Patients who have been using donepezil, galantamine, or rivastigmine at a fixed dose for the past three months. 6) Patients who have signed an informed consent form for participation in the study, who can be contacted frequently by the patient, and who have a trustworthy study partner (parents, siblings, children/grandchildren, relatives living in the same household, or persons considered to be equivalent to such close relatives) who can respond at designated times.
Exclusion criteria
Exclusion criteria: 1) Receiving non-pharmacological therapy for the treatment of AD 2) Taking Kampo Medicine 3)Regularly consume health functional foods that may influence the study three or more times per week and cannot discontinue them within three weeks prior to the study start date 4)Prior experience of anti-amyloid beta antibody drug therapy 5) Taking Memantine 6) Kidney disfunction (eGFR100mg/dl 8)Change of drug dosage or type that could affect the progression cognitive function during the three months 9) Complication with gastric ulcer, bronchial asthma, or epilepsy. 10) Judged by doctors not to be suited for study, such as having serious complications
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ADAS-Jcog | — |
Secondary
| Measure | Time frame |
|---|---|
| Disability assessment of Dementia Grip strength Advanced Glycation End Products | — |
Contacts
Universtiy of Toyama